In a research report published this morning, Bank of America is pleased with GlaxoSmithKline's GSK offer of $13 per share for Human Genome Sciences HGSI.
According to Bank of America, "In our view, the deal continues to make sense. GSK is already partnered on a number of assets namely Benlysta (Lupus, marketed); Albiglutide (PIII GLP-1 analogue for diabetes); Darapladib ( PIII LpPLA2 inhibitor for atheroslerosis) and Rilapladib (PII LpPLA2 inhibitor for Alzhiemer's). We believe the deal offers scope to remove inefficiencies in the JV structures yielding c3% out-year EPS accretion and 4p-51p of NPV accretion depending on pipeline success. We do not expect GSK to raise the offer to value-destructive levels given lack of a natural alternative bidder and its strict IRR criteria for bolt-on M&A."
Bank of America maintains its Buy rating and $55.12 PO on GlaxoSmithKline, which closed yesterday at $46.57.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in